Trial Profile
Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Depatuxizumab mafodotin (Primary) ; Steroids; Temozolomide; Vasoconstrictors
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Registrational
- Acronyms UNITE Study
- Sponsors AbbVie; AbbVie Germany
- 19 Mar 2021 Status changed from completed to discontinued because clinical development of depatuxizumab mafodotin inglioblastoma was stopped due to lack of survival benefit.
- 31 Oct 2020 This trial has been Suspended in Netherlands, according to European Clinical Trials Database record.
- 02 Apr 2020 Status changed from suspended to completed.